NASDAQ 2.73%. This suggests a possible upside of … MEI Pharma Inc. 2.76 0.17 (6.36%) MEI Pharma Inc. NASDAQ Updated May 14, 2021 3:48 PM. Vous pouvez sélectionner l’option « Personnaliser mes choix » afin de gérer vos préférences. About the MEI Pharma Inc stock forecast. The high price target for MEIP is … -0.04 / -1.49%. Kohl’s Stock Got Slammed After a Strong Earnings Report. All quotes are in local exchange time. The ratio of debt to operating expenses for MEI Pharma Inc is higher than it is for about merely 12.53% of US stocks. Delayed Data. MEI Pharma started at buy with $16 stock price target at SunTrust RH May. MEIP 2.76 0.17 (6.36%) Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. … Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The average price target represents a 196.92% upside from the last price of $3.57. Its drug candidates include Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Their average twelve-month price target is $10.60, predicting that the stock has a possible upside of 294.05%. It Looks Like a Bargain. Today’s Change. MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. What’s Next for Bond Yields, Gold Prices, and Cryptocurrency Regulation, A Pharma Start-Up Takes a Crack at Blockbuster Drug Prices, MEI Pharma started at buy with $16 stock price target at SunTrust RH, MEI Pharma shares jump 51% in pre-market trade after $20 mln drug deal, MEI Pharma Shares to Remain Near Cash Level, Alliance Global Partners Reaffirms Their Buy Rating on MEI Pharma (MEIP), H.C. Wainwright Sticks to Their Buy Rating for MEI Pharma (MEIP), MEI Pharma, Inc. (MEIP) Reports Q3 Loss, Misses Revenue Estimates, Analysts Estimate MEI Pharma, Inc. (MEIP) to Report a Decline in Earnings: What to Look Out for, Brookline Capital Markets Keeps a Buy Rating on MEI Pharma (MEIP), Analysts Offer Insights on Healthcare Companies: MEI Pharma (MEIP) and NovoCure (NVCR), MEI Pharma Presents Positive Preclinical Data For Cancer Drug Voruciclib, Brookline Capital Markets Maintains Their Buy Rating on MEI Pharma (MEIP), LifeSci Capital Believes MEI Pharma (MEIP) Still Has Room to Grow, H.C. Wainwright Believes MEI Pharma (MEIP) Won’t Stop Here, Alliance Global Partners Sticks to Its Buy Rating for MEI Pharma (MEIP), Analysts Have Conflicting Sentiments on These Healthcare Companies: MEI Pharma (MEIP), Soleno Therapeutics (SLNO) and Gilead Sciences (GILD), Analysts Are Bullish on These Healthcare Stocks: MEI Pharma (MEIP), Soleno Therapeutics (SLNO), Analysts Offer Insights on Healthcare Companies: MEI Pharma (MEIP) and Soleno Therapeutics (SLNO), MEI Pharma (MEIP) Gets a Buy Rating from H.C. Wainwright, MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Tops Revenue Estimates, MEI Pharma, Inc. (MEIP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release, Analysts Are Bullish on Top Healthcare Stocks: MEI Pharma (MEIP), Cogent Biosciences (COGT). Wall Street Stock Market & Finance report, prediction for the future: You'll find the MEI Pharma share forecasts, stock quote and buy / sell signals below.According to present data MEI Pharma's MEIP shares and potentially its market environment have been in bearish cycle last 12 months … Big Oil’s Transition to Cleaner Energy Won’t Be Easy. Mei Pharma's future stock price is the expected price of Mei Pharma stock. Get MEI Pharma Inc (MEIP:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. MEI Pharma, Inc. stock is held by 146 institutions, with MPM ONCOLOGY IMPACT MANAGEMENT LP being the largest institutional investor. Copyright © 2021 MarketWatch, Inc. All rights reserved. Latest Share Price and Events Stable Share Price : MEIP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week. As of 2021 May 02, Sunday current price of MEIP stock is 3.620$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. MEI Pharma stock price as been showing a rising tendency so we believe that similar market segments were very popular in the given time frame. MEI Pharma’s portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U. Note the wide gap in analyst price targets? MEI Pharma’s portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support an accelerated approval marketing application with the U. View MEI Pharma, Inc. MEIP investment & stock information. Use the Zacks Rank and Style Scores to find out is MEIP is right for your portfolio. By Dec 30, 2020, it held 9.01% of the shares, which is about 10.14 Million shares worth $26.76 Million. Today ||| 52-Week Range. Nasdaq 100. ET by Tomi Kilgore MEI Pharma shares jump 51% … Informations relatives à votre compte, à votre appareil et à votre connexion internet, y compris votre adresse IP, Informations relatives à votre navigation et historique de recherche lors de l’utilisation des sites web et applications de Verizon Media. MEI Pharma, Inc. (NASDAQ:MEIP)’s Biggest Investors. MEI Pharma Possible wedge breakout MEI Pharma is a pharmaceutical company, which engages in the clinical development of therapies for cancer.
MEIP MEI Pharma Inc. — Stock Price and Discussion | Stocktwits. MEIP: Get the latest MEI Pharma stock price and detailed information including MEIP news, historical charts and realtime prices. Our portfolio of drug candidates includes Pracinostat, an oral HDAC inhibitor being developed in combination with azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).Our clinical … Cookie Notice (). There are currently no items in this Watchlist. S&P 500 2.24%. Our portfolio of drug candidates contains four clinical-stage candidates, including one candidate (zandelisib) in a Phase 2 clinical trial which we intend to submit to the U.S. Food and Drug administration to support an accelerated approval marketing application. 7 brokerages have issued 1-year target prices for MEI Pharma's stock. Additionally, MEI Pharma Inc scored a 83 in the Healthcare sector, ranking it higher than 83% of stocks in that sector. Intraday data delayed at least 15 minutes or per exchange requirements. 7 Wall Street analysts have issued ratings and price targets for MEI Pharma in the last 12 months. Trending now. MEI Pharma Inc is around the top of the Healthcare sector according to InvestorsObserver.MEIP received an overall rating of 31, which means that it scores higher than 31% of stocks. I am not a financial advisor. According to 8 analysts, the average rating for MEI Pharma stock is "Strong Buy." By using this site you agree to the
Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. Have Watchlists? On average, they anticipate MEI Pharma's share price to reach $10.60 in the next year. Real time MEI Pharma (MEIP) stock price quote, stock graph, news & analysis. How Investors Can Prepare. MEI Pharma, Inc. Common Stock (MEIP) MEI Pharma, Inc. Common Stock. MEI Pharma Inc () Stock Market info Recommendations: Buy or sell MEI Pharma stock? Historical and current end-of-day data provided by FACTSET. The all-time high MEI Pharma stock closing price was 766.05 on February 11, 2004. Intraday Data provided by FACTSET and subject to terms of use. In comparing MEI Pharma Inc. (MEIP)’s stock with other industry players reveals that stock’s current price change of -0.3% and that of +26.82% over the past 12 months is in competing position with that of Zoetis Inc Cl A (ZTS) which saw its stock price raised by 2.41% in the last trading and went through an increase of 38.08% in past 12-month trading. Find the latest MEI Pharma, Inc. (MEIP) stock quote, history, news and other vital information to help you with your stock trading and investing. DOW 1.97%. The stock currently has a share float of 71.4%. Mei Pharma stock is selling at 3.55 as of the 29th of April 2021; that is -1.11 percent decrease since the beginning of the trading day. The most optimistic MEI Pharma analyst has a price target of US$13.00 per share, while the most pessimistic values it at US$5.50. Should I buy Mei Pharma, Inc. (MEIP)? Subscriber Agreement & Terms of Use,
Get the latest Mei Pharma detailed stock quotes, stock trade data, stock price info, and performance analysis, including Mei Pharma investment advice, charts, stats and more. We are a San Diego-based late-stage pharmaceutical company focused on developing potential new therapies for cancer. En cliquant sur « Tout accepter », vous consentez à ce que Verizon Media et ses partenaires stockent et/ou accèdent à des informations sur votre appareil par l’intermédiaire de cookies et technologies similaires, et traitent vos données personnelles, afin d’afficher des publicités et contenus personnalisés, mesurer les performances des publicités et contenus, analyser les audiences et développer les services. Investors. The stock's last reported lowest price was 3.51. Are there signs that big gains could be coming in the near future? MEI Pharma (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. Their forecasts range from $9.00 to $13.00. 29, 2020 at 7:25 a.m. This price target is based on 7 analysts offering 12 month price targets for MEI Pharma in the last 3 months. The MEI Pharma 52-week high stock price is 4.58, which is 35.5% above the current share price. The average price target is $10.60, with a high forecast of $13.00 and a low forecast of $9.00. Privacy Notice, and
Pour en savoir plus sur la façon dont nous utilisons vos informations, veuillez consulter notre Politique relative à la vie privée et notre Politique en matière de cookies. The latest closing stock price for MEI Pharma as of April 16, 2021 is 3.38. MEI Pharma Inc (NASDAQ:MEIP) MEI Pharma Inc. 2.65. The 12-month stock price forecast is 9.67, which is an increase of 172.39% from the latest price. Stock Information Events & Webcasts SEC Filings Annual Report Analyst Coverage Corporate Governance News Alerts Contact IR Financial Reporting Careers; Contact Something went wrong while loading Watchlist. This browser is no longer supported at MarketWatch. We are a San Diego-based late-stage pharmaceutical company focused on developing potential new therapies for cancer. Visit a quote page and your recently viewed tickers will be displayed here. Over the past twelve months, MEIP has reported earnings growth of 158.64%, putting it ahead of 89.08% of US stocks in our set. Vous pouvez modifier vos choix à tout moment en consultant Vos paramètres de vie privée. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest MEI Pharma, Inc. MEIP detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. En cliquant sur « Tout refuser », vous refusez tous les cookies et technologies similaires dits non-essentiels mais Verizon Media continuera à utiliser des cookies et technologies similaires exemptés du consentement. (MEIP) Nasdaq Listed. In this video, we take a look at MEIP. As of May 18. For the best MarketWatch.com experience, please update to a modern browser. The company was founded on December 1, 2000 and is headquartered in San Diego, CA. MEIP Stock Summary. Create a list of the investments you want to track. MEI Pharma, Inc. has a market cap of $416.4 Million and is expected to release its quarterly earnings report on February 04, 2021. A high-level overview of MEI Pharma, Inc. (MEIP) stock. We are a San Diego-based, late-stage pharmaceutical company focused on developing potential new therapies for cancer. How has MEI Pharma's share price performed over time and what events caused price changes? Upon looking at major shareholders, it appears that insiders hold 2.82% of MEI Pharma, Inc. shares, and 69.38% of them are in the hands of institutional investors. 2.29. It is based on its current growth rate as well as the projected cash flow expected by the investors. With its Forward Dividend at 0 and a yield of 0%, the company’s investors could be worried for the MEIP stock to … Data is currently not available. ABOUT US. $2.76. Log in to see them here or sign up to get started. Squarespace Breaks From the Pack and Goes Public Directly, Cisco Can Overcome the Global Chip Shortage, After the Spinoff: The Winners and Losers.
Success Indicator In Reading,
Monica Sementilli And Robert Louis Baker,
Asc 321 Ey,
West Preparatory Academy,
San Marino Eurovision 2017,
Story In French,
Oak Hill Country Club Employment,